Areteia Therapeutics Overview
- Year Founded
-
2022
- Status
-
Out of Business
- Employees
-
35
- Latest Deal Type
-
Out of Business
Areteia Therapeutics General Information
Description
Developer of an oral medication intended to treat eosinophilic asthma. The company's platform is focused on developing an oral drug that inhibits eosinophil maturation, showing potential to reduce inflammation and alleviate symptoms of severe asthma, enabling asthma patients to manage their condition more effectively while offering a more accessible alternative to injectable therapies.
Contact Information
Website
www.areteiatx.comCorporate Office
- 101 Glen Lennox Drive
- Suite 300
- Chapel Hill, NC 27517
- United States
Corporate Office
- 101 Glen Lennox Drive
- Suite 300
- Chapel Hill, NC 27517
- United States
Areteia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | Completed | Out of Business | ||||
| 3. Early Stage VC | 01-May-2025 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series A1) | 12-Feb-2024 | $425M | $425M | Completed | Clinical Trials - Phase 3 | |
| 1. Spin-Off | 01-Jan-2022 | Completed | Clinical Trials - Phase 1 |
Areteia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A-2 |
Areteia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Areteia Therapeutics Patents
Areteia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250352520-A1 | Use of dexpramipexole for the treatment of eosinophilic copd | Inactive | 17-May-2024 | ||
| WO-2025240942-A1 | Use of dexpramipexole for the treatment of eosinophilic copd | Pending | 17-May-2024 | ||
| AU-2024404682-A1 | Matrix tablets of dexpramipexole and methods of manufacturing and use thereof | Pending | 20-Dec-2023 | ||
| EP-4827846-A1 | Matrix tablets of dexpramipexole and methods of manufacturing and use thereof | Pending | 20-Dec-2023 | ||
| US-20250205207-A1 | Matrix tablets of dexpramipexole and methods of manufacturing and use thereof | Pending | 20-Dec-2023 | A61K31/428 |
Areteia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Areteia Therapeutics FAQs
-
When was Areteia Therapeutics founded?
Areteia Therapeutics was founded in 2022.
-
Where is Areteia Therapeutics headquartered?
Areteia Therapeutics is headquartered in Chapel Hill, NC.
-
What is the size of Areteia Therapeutics?
Areteia Therapeutics has 35 total employees.
-
What industry is Areteia Therapeutics in?
Areteia Therapeutics’s primary industry is Drug Discovery.
-
Is Areteia Therapeutics a private or public company?
Areteia Therapeutics is a Private company.
-
What is Areteia Therapeutics’s current revenue?
The current revenue for Areteia Therapeutics is .
-
How much funding has Areteia Therapeutics raised over time?
Areteia Therapeutics has raised $425M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
